GSK and Novartis have struck a deal that will move all of GSK's oncology assets to Novartis, all of Novartis' non-flu-related vaccines to GSK, and will result in a joint consumer healthcare venture.
The FDA has approved the VEGFR-2 inhibitor ramucirumab as a treatment for patients with patients with unresectable gastric cancer or gastroesophageal junction adenocarcinoma, based on a significant extension in OS.
Talimogene laherparepvec significantly improved durable response rates but failed to extend overall survival in patients with advanced melanoma.
The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.
Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.
A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.
An updated guideline from ASCO regarding the use of sentinel lymph node (SLN) biopsy in early stage breast cancer supports the use of the procedure over axillary lymph node dissection (ALND) in a larger group of patients than previously recommended.
Five early-phase clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy have been suspended temporarily in response to the deaths of 2 patients with adult B-cell acute lymphoblastic leukemia